Psoriasis Flashcards

1
Q

casues/Risk factors of Psoriasis

A

1) Enviromental –> cold weather, trauma, infectio, alcohol and certain drugs (e.g,Steroid withdrawel)
2) Genetic –> Human leukocyte antigen Cw6 (HLA-Cw6) gene, IL-23R and IL-12.
3) Immnulogic –> High levels of dermal and circulating TNF- α
- increased activity of T cells in the underlying skin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

clinical presentation of Psoriasis

A

1) skin rash
2) itching
3) fine scaling
4) pain
5) Generalized erythema

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Non-pharmacological management of Psoriasis

A
  • Stress reduction.
  • Reduce alcohol and smoking.
  • Climatotherapy, sun exposure, emollients
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Pharmacogical management of Psoriasis

A

1) Topical medication
2) Phototherapy and psoralens
3) Topical Corticosteroids
4) Ophthalamic Corticosteroids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

indication of Topical Corticosteroids

A

mild to moderate plaque psoriasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

MoA of Topical Corticosteroids

A

reduce plaque formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Adverse effects of Topical Corticosteroids

A
  • Skin atrophy, striae, allergic dermatitis.
  • Slow withdrawal to avoid sudden flares.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Exmaples and Topical Steroids and their indication

A

1) Hydrocortisone topical –> mild potency – for face.
2) Betamethasone topical –> strong potency – truncal area

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Indication of Betamethasone topical

A

Strong potency- truncal area

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Indication of Hydrocotisone Topical

A

Mild potency- for face

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

indication of Ophthalmaic Corticosteroids

A
  • Treat conjunctival and corneal inflammation.
  • Control infiltration and delay vascularization.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Opthalmaic corticosteroids

A

1) Prednisolone ophthalmic.
2) Betamethasone ophthalmic.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

AE of Systemic Corticosteroids

A

–> IM corticosteroids are not recommended
for the management of psoriasis.
– >High risk of flare upon withdrawal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Indication of Vitamine D analogues

A

mild to moderate plaque
psoriasis
in combination with steroids
–> Used in patients with lesions on the faceor
exposed areas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Category of Calcipotriol Topical

A

vitamin D Analog

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

MoA of Calcipotriol topical

A

–> Inhibits epidermal proliferation.
* Less irritating in sensitive areas of skin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

indication of Calcipotriol tropical

A

mild to moderate plaque psoriasis in combination with steroids
–> on the FACE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Category of Methotrexate

A

Cytotoxic/Immunosuppressive drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Indication of Methotrexate

A

symptomatic control of severe,
refractory, disabling psoriasis

20
Q

PK/PD of Methotrexate

A

Can be used for as long as it remains effective and well-tolerated.

21
Q

Adverse effetcs of Methotrexate

A

1) Monitor patients closely for bone marrow, liver,
lung and kidney toxicities

2) Teratogenic – contraindicated in pregnancy

22
Q

Category of Apremilast

A

PED4 inhibitor
*PED4 : Phosphodiesterase-4 inhibitor

23
Q

MoA of Apremilast

A

increase in cAMP which causes an increased gene expression of anti-inflammatory mediators

24
Q

Indication of Apremilast

A

moderate-to-severe plaque psoriasis in
candidates for phototherapy or systemic therapy and
for patients with active psoriatic arthritis

25
Q

Adverse effects of Apremilast

A

1) Nausea,
2) headache

26
Q

Category of Infliximab, etanercept, adalimumab

A

TNF-α inhibitors

27
Q

MoA of Infliximab, etanercept, adalimumab

A

neutralize the effects of TNF-α.

28
Q

Indication of Infliximab, etanercept, adalimumab (TNF-α inhibitors)

A

1) chronic, severe plaque psoriasis in candidates for systemic therapy and when
other systemic therapies are medically less appropriate
2) reducing signs and symptoms in patients
with active psoriatic arthritis

29
Q

Adverse effects of Infliximab, etanercept, adalimumab

A

1) infections,
2) infusion reactions

30
Q

Category of Ustekinumab

A

Interleukin Inhibitor

31
Q

MoA of Ustekinumab

A

monoclonal antibody directed against
interleukin-12 and interleukin-23 → interferes with T-cell differentiation and activation

32
Q

Indication of Ustekinumab

A

moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy and also for patients with active psoriatic arthritis

33
Q

Adverse effects of Ustekinumab

A

1) infections,
2) back pain

34
Q

Category of Acitretin

A

Retinoids

35
Q

Administration of Acitretin

A

Orally

36
Q

Indication of Acitretin

A

1) severe extensive plaque psoriasis resistant to other forms of therapy and also for
2) first-line treatment of pustular psoriasis

37
Q

MoA of Retinoids

A

vitamin A analogue

*MoA of oral retinoids same as of topical retinoids (e.g.
tazarotene topical).

38
Q

Precautions followed during the use of Retinoids

A

1) Category X medication - teratogenic
2) Contraindicated in pregnancy and hyperlipidaemia
3) Use of sunscreens during treatment and avoid exposure to sunlight.
4) Avoid use of alcohol.

39
Q

Adverse effects of Acitretin (oral)

A

1) hepatotoxicity,
2) cheilitis (inflammation of the lips)
3) alopecia,
4) skin peeling.

40
Q

Adverse effects of Tazarotene (Topical Retinoid)

A

1) desquamation,
2) pruritus,
3) erythema,
4) burning.

41
Q

the 2 types of Phototherapy treatments of Psorisis

A

1) UVB- ultraviolet B light
2) PUVA- Psoralen and ultraviolet A

42
Q

MoA of UVB

A

UVB penetrates the skin and slows the growth of affected skin cells.

43
Q

MoA of PUVA

A

UVA is relatively ineffective unless used w/ a light-sensitive meciation called psoralen (topically or orally)

44
Q

Indication of UVB and PUVA

A

1) extensive and widespread disease or
2) resistance to topical treatment in combination with other pharmacological treatment

45
Q

Adverse effects of PUVA treatment

A

higher risk of skin cancer